CDK4 and breast carcinoma: Clinical studies have demonstrated that addition of selective CDK4/6 inhibitor palbociclib to letrozole or fulvestrant showed an improvement in median progression-free survival (PFS) in patients with HR-positive advanced-stage breast cancer (Finn et al., 2015; Cristofanilli et al., 2016).